TL;DR
T(14;16) translocation is frequently accompanied by 1q21 gain/amplification and is a poor prognostic factor for OS and PFS in patients with newly diagnosed multiple myeloma.
Children of Xp11.2 tRCC predominantly presents primarily with gross hematuria, and AJCC stage Ⅲ-Ⅳ and the presence of regional lymph node metastasis were both associated with disease progression and recurrence.
ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor. However, recent evidence suggests that MM with t(11;14) exhibits heterogeneous biological characteristics and clinical outcomes distinct from those associ...
ABSTRACT Circulating tumor DNA (ctDNA) serves as a non‐invasive liquid biopsy technique, offering potential utility in the prognostic evaluation of multiple myeloma (MM). In this study, we performed a systematic review and updated meta‐analysis to analyze the association between ctDNA and the prognosis of patients diag...
Purpose Conventional radiologic assessment using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) may not fully capture clinical responses during immunotherapy. Therefore, we investigated the association between early weight gain (WG) and prognosis in this population. Materials and Methods We enrol...
The prognostic impact of the diagnosis-to-treatment interval (DTI) in diffuse large B-cell lymphoma (DLBCL) remains controversial. We investigated the association between DTI and three-year all-cause mortality in a nationwide cohort. We conducted a retrospective population-based cohort study using harmonised German can...
Surgery remains the cornerstone of treatment for pediatric NRSTS, and complete resection is the most important prognostic determinant, as most low-risk children can be cured without adjuvant chemotherapy or radiotherapy.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
